Owen A. O’Connor, M.D., Ph.D.

Founder, Chair and Chief Executive Officer (CEO)

Owen O’Connor is the Founder, Chair, and Chief Executive Officer of Nouveau Biosciences, where he has led the company’s evolution into a drug-focused biotechnology platform advancing novel nanotherapeutics for cancer. By integrating synthetic lethality screening, genomics, and computational biology, Nouveau has developed a pipeline of differentiated oncology therapies, including its lead candidate, Kromastat, which has shown strong potential across T-cell malignancies, pancreatic cancer, and aggressive leukemias. Under Dr. O’Connor’s leadership, the company has secured substantial financing and established strategic collaborations globally to advance its clinical programs.

A world-renowned physician-scientist, Dr. O’Connor has led the global regulatory approval of multiple therapies in oncology and autoimmune disease and holds numerous patents related to cancer treatment. He has held academic and faculty appointments at Cornell University Medical Center, Memorial Sloan Kettering Cancer Center, and Columbia University, among others. With more than 300 publications and multiple books on lymphoma and targeted cancer therapies, Dr. O’Connor is widely recognized for combining scientific innovation with visionary leadership in biotechnology and medicine.